Science Share Discussion Threads

[yoyoy] 11/1/2011 07:06

Sagentia Group PLC

11 January 2011


Press Release 11 January 2011

Sagentia Group plc

("Sagentia" or the "Group")

Pre-Close Trading Update

Sagentia Group plc (AIM:SAG), the international technology consulting company which provides outsourced R&D consultancy services, reports the following pre-close trading update.

Trading Update

Sagentia's interim results were released on 21 July 2010 when a strong turnaround in the Group's operating performance was reported. A further trading update was released on 11 October 2010, confirming the continued recovery.

The progress made throughout 2010 has been maintained through to the year end. As a result, subject to audit, the Board now anticipates reporting revenue for the year in excess of GBP20 million and profit before tax in excess of GBP2.0 million, significantly ahead of market expectations.

The Group's preliminary results are anticipated to be released in late February 2011.

[truffle] 16/12/2010 17:35

Many thanks.

[interceptor2] 16/12/2010 16:53

The 50ma often acts as a support when a share is advancing, and it's worth keeping an eye on this level for how the price reacts. A growth company in a general advance should on the whole stay above this level, small dips below are normal as long as they dont remain below for too long.

Regards ic2..........

[truffle] 16/12/2010 12:36

Read the link but not sure how you apply it to a share price in a simple meaningful way to obtain an opinion one way or the other.
If this is easily explained then fine, if not don't worry.

[chester] 16/12/2010 07:24

50 ma = 50 moving average.

[truffle] 16/12/2010 07:12

Not sure what '50ma' means?

Anyway, looks really good and Arbuthnot had an 85p target a couple of months ago so hope we may be heading that way.

[interceptor2] 15/12/2010 18:38

OK I'll make a comment.

Heading for a break out on increasing volume after bouncing of the 50ma.

Hows that?

Regards ic2.......

[rafieh] 15/12/2010 18:24

More than 5% advance in one day, and no one on this board cares to comment!

[interceptor2] 09/12/2010 13:17

That was lucky, just brought in time, before todays move started.

Healthy increase in volume today lookd promising.

[cockneyrebel] 09/12/2010 12:22

Hi interceptor - good move imo :-)

Looking good today. Ratclyff looks a shrewed and well connected cookie imo.

CR

[interceptor2] 09/12/2010 09:49

Brought in this morning, have been keen to buy in for some time. I like the chart consolidation on the 50 ma support, and good to see the new Finance Director making a second purchase @58p.

I like the management team here led by Brent Hudson, backed up now by a new FD Neil Elton who was successful at Conateno before the takeover.

Hopefully they will release a pre close trading update before the Finals in February.

Regards ic2.......

[cockneyrebel] 05/12/2010 13:28

Sagentia gets £8 million


Lloyds TSB has signed an £8 million loan deal with Sagentia, the technology consultancy at Harston. The money, which is there for five years, will be used for working capital and to buy other businesses.

Neil Elton, finance director, said: "Sagentia has seen strong sales growth and margin improvement during 2010.

"Along with a successful placing in May, the new loan facility agreed with Lloyds TSB means the group is in a strong position to develop the business through acquisition and organic growth."

Sagentia has 140 employees working out of their Harston Mill headquarters and further offices in Boston, US, and Hong Kong.

Richard Faircloth, from Lloyds TSB Corporate Markets in Cambridge, said: "The management team at Sagentia is eager to expand its operations in the technology sector and we've worked in partnership with them to lay the financial groundwork for this growth.

"The financial package we've put together should enable the business to realise its ambitions and we look forward to developing our already close relationship with this key player in the local economy.

"With investment in cutting edge technology being supported by the Government as an important measure in securing Britain's economic regeneration, firms like Sagentia are expected to be leading economic drivers in the country's recovery. Our investment will support the company as it builds on its 24 years in the industry."

[cockneyrebel] 02/12/2010 14:27

buyers today and going through the recent resistance here.

CR

[electronica] 30/11/2010 09:53

hastings - thanks for that local rag piece on Sagentia, very interesting & pretty encouraging.

I've just dipped a toe back in with these guys & am looking for reasons to put more cash in. As one of the founders of the original Scientific Generics company (along with Gordon Edge & Peter Moody) I've got a v strong sentimental attatchment to SAG. Perhaps SAG will make me as much cash as happened during my "working insider" days.

[cockneyrebel] 26/11/2010 15:37

Cheers Steg :-)

Moving up today - some rather large trades.

CR

[stegrego] 22/11/2010 08:22

For immediate release
22 November 2010
 
 
 
Sphere Medical Holding PLC
 ("Sphere Medical", "Sphere" or "the Company")
                
                                                                               
       
Sphere Medical achieves CE Marking for the Pelorus 1000 the World's first commercially available propofol analyser
 
 

22 November 2010: Sphere Medical, the UK-based medical sensor innovator, has achieved CE Marking for their Pelorus 1000 propofol measurement system, which offers the unique capability to rapidly measure concentrations of the intravenous anaesthetic propofol in whole blood samples.

Propofol is widely used in critical care, for general anaesthesia in the operating room and for sedation in the intensive care unit. At the present time, the concentration of intravenous anaesthetics in the blood stream cannot be measured in real time. The ability to titrate propofol to whole blood concentration is expected to be a key tool in individualising and optimising therapy at the patient level, both in the operating room and the intensive care unit.

The Pelorus 1000 offers the clinical researcher, for the first time, the ability to carry out studies which require real time drug concentration measurement, rather than retrospective sample analysis.

 
Stuart Hendry, CEO of Sphere Medical, said: "I am extremely pleased that Sphere has been able to bring this innovation to the market following successful clinical trials earlier this year, some of which were published at the ASA.  We are already working with leaders in the critical care field and I look forward with anticipation to the studies being performed that will begin prove the clinical and economic benefits of real time measurement of propofol concentration."
 

About Sphere Medical
Sphere Medical is developing highly innovative monitoring products to provide clinical and economic benefits in the critical care environment, based on the company's proprietary microsensor technology. The products allow minimally invasive, real time measurement of clinical chemistry parameters and therapeutic drug concentrations, giving healthcare professionals the information they require to more effectively manage therapy and optimise patient outcomes. Sphere Medical was founded in 2002 and is based in Cambridge, UK.
 
For more information, please visit www.spheremedical.com, or contact:
 
Dr. Stuart Hendry                                            Tim Anderson
Chief Executive Officer                                        Buchanan Communications
Sphere Medical Holding PLC                               Tel: [phone]
Tel: [phone]                                                            
 
                                   
 

[cockneyrebel] 17/11/2010 11:06

Buyers moving in after that director buy this am.

CR

[cockneyrebel] 11/11/2010 11:00

Back on the up today UK-I

punters looking at the full year forecasts and not the 3.8p eps in H1 imo.

CR

[ukinvestor220] 10/11/2010 07:48

OK whos been selling these then.

[yoyoy] 06/11/2010 08:34

That was a large and unexpected drop.

A quick trawl og google reveals no apparent reason.

In fact a new agrrement in the last few days


"Titan Medical Inc. ("the Company") (TSX VENTURE:TMD) announced today that it has signed an agreement with Sagentia Inc., a world leading technology and product development company, for the industrial design and development of certain core aspects related to the Company's Amadeus robotic surgical system.

Under the terms of the agreement, Sagentia will work with Titan to develop the core structure and mechanisms of the Surgeon Console, from front end needs analysis through to transfer to manufacture, in order to aid in the delivery of innovation and commercial value of the Amadeus Platform.

Dr. Reiza Rayman, President of Titan Medical Inc., commented, "We are proud to join Sagentia's client base which includes leading multinational medical manufacturers and high innovation start-ups. This partnership will enable us to accelerate development of Amadeus in its final pre clinical phase, while adhering to the highest technological standards in the industry."

Brent Hudson, Chief Executive Officer of Sagentia, said, "We are excited about this opportunity to collaborate with Titan Medical on developing its cutting edge robotic surgery system. We are pleased to be Titan's selected partner, leveraging our strengths in complex R&D product development requirements and helping the company to bring its innovative value proposition to the market."

About Sagentia

Sagentia is a technology and product development company, working with clients from front end needs analysis to transfer to manufacture. Established in 1986, the company's commitment to innovation has led to the launch of new technologies and products that change the basis of competition. Sagentia's teams are situated in state-of-the-art facilities in the US, Europe and China. For more information, visit www.sagentia.com.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The current global robotic surgical market size is approximately $1 billion and is estimated to grow to $5 billion by 2015 with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com."

[maxwellsdemon] 12/10/2010 09:19

Newspaper Headlines – 12 October 2010

The Times

Tiddler to Watch: Sagentia shares advanced 3½p to 70p on AIM, their best since 2007. The Cambridge-based consultancy, which advises the likes of Vodafone about its technology and processes, again reassured investors that profits would be well ahead of previous forecasts. In response, Rob Sanders at Arbuthnot, its broker, lifted his target price for the shares from 71p to 85p.

[ron manager] 11/10/2010 11:01

House broker's morning note reads....

Sagentia's trading update reads very positively with the core consultancy business continuing to perform ahead of expectations. Utilisation levels have remained high over the summer, due to a combination of more work with existing clients and new client wins. As a result of this, we have increased our adjusted PBT forecast for FY2010 from £1.2m to £1.7m on revenues of £18.0m (£17.1m) leading to EPS of 4.1p (2.8p). At this stage, we have increased our PBT forecasts by £0.5m for FY2011 to £2.2m (£1.7m) and a more conservative £0.1m for FY2012 to £2.4m (£2.3m). As well as beating profit forecasts, the net cash position of £8.3m as at October 1st is well ahead of our £7.0m forecast for FY2010.

A new five-year loan has been negotiated against the freehold property which is not subject to any covenants on the consultancy business (save keeping cash balances of £2m) and following an interest rate swap is fixed at around 4.8%. This is part of a general cleaning-up of the corporate structure which should mean that the company is capable of continuing to meet/beat expectations. With the upgraded forecasts, we have increased our target price from 71p to 85p and maintain our Strong Buy recommendation.

[chester] 11/10/2010 08:50

"significantly ahead" are the words you like to hear. Mine are safely tucked away in my SIPP.